ArticleIn vivo (Athens, Greece)
Laryngeal and Hypopharyngeal Malignancies: Where Do We Stand? A Retrospective Single-center Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimSquamous cell carcinoma (SCC) of the larynx and hypopharynx shows subsite-specific patterns, with supraglottic tumors closely resembling hypopharyngeal SCC. This study aimed to analyze 10-year epidemiologic trends, management, and outcomes in a tertiary hospital, with emphasis on prognostic similarities between supraglottic and hypopharyngeal tumors. PATIENTS AND
methodsA retrospective cohort of 454 patients with laryngeal or hypopharyngeal SCC (2012-2022) was evaluated. Demographic characteristics, TNM stage, treatment modality, and 5-year disease-specific survival (DSS) were analyzed.
resultsHypopharyngeal SCC cases were predominantly advanced (T3-T4: 66.4%; N2-N3: 82.7%) and more often metastatic (29.8%), compared with laryngeal SCC (40.6%, 21.1%, and 5.4%, respectively;
conclusionOver the past decade, the incidence, demographics, and stage distribution of laryngeal and hypopharyngeal SCC remained stable. Although laryngeal SCC management increasingly favored organ preservation, hypopharyngeal SCC persisted as an advanced-stage disease primarily treated with non-surgical approaches. Five-year DSS remained substantially poorer for hypopharyngeal SCC. Supraglottic laryngeal tumors shared clinical and prognostic characteristics with hypopharyngeal SCC, including advanced stage, high metastatic rate, and inferior survival. The notable prevalence of distant metastases-nearly 30% in hypopharyngeal and 10% in supraglottic SCC-underscores the importance of incorporating PET/CT or PET/MR into baseline staging and highlights the need for multicenter studies to optimize management of these high-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.